All In MedTech

Device Trial Radar · NCT02747264

eRAPID Feasibility Pilot Study in Pelvic Radiotherapy

eRAPID Electronic Patient Self-Reporting of Adverse-events: Patient Information and aDvice: Feasibility Pilot Study in Radiotherapy

Last checked: Nov 19, 2026Latest source record: Apr 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 167 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

167

Actual

Start

Dec 1, 2016

Primary completion

Jun 1, 2018

Study completion Oct 30, 2018

Sponsor

Lead sponsor
University of LeedsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Leeds Teaching Hospitals NHS Trust; The Christie NHS Foundation Trust
First posted
Apr 21, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the Electronic Patient Self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) programme is to determine whether eRAPID (an online system for patients to self-report symptoms and side effects) can enhance patient care and improve the safe delivery of cancer treatments. The investigators hypothesise that patient symptoms will be detected earlier with more timely admissions and a reduction in overall hospital contacts. It is predicted that staff will save time recording symptoms and side effects and will be able to focus attention during clinical contacts on more severe side effects. eRAPID is a cost-effective approach to supporting patient self-management and reducing hospital/General Practitioner (GP)/community contacts. The majority of the research will be run with systemic patients. This particular part of the research is a feasibility study in radiotherapy (RT) patients to test the platform in a different patient group.

Conditions

  • Cancer

Interventions

  • eRAPIDDevice

    eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with self-reported outcome data at each time-pointTime frame: 6 months
  2. Proportion of missing data in patient outcome questionnairesTime frame: 6 months
  3. Appropriateness of patient outcome questionnaires by assessing ceiling and floor effects ( quality of life questionnaire)Time frame: 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Christie Hospital

    Manchester, Greater Manchester, United Kingdom

  • St James University Hospital

    Leeds, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.